NLC-Based Rifampicin Delivery System: Development and Characterization for Improved Drug Performance Against Staphylococcus aureus
Year: 2025
Type: article
Abstract: Background/Objectives: Rifampicin is a typical antibiotic used for the treatment of Staphylococcus aureus (S. aureus) infections; however, its clinical utility is limited by poor aqueous solubility, chemical instability, and increasing bacterial resistance. Nanostructured lipid carriers (NLCs) offer a promising strategy to improve drug solubility, stability, and antimicrobial performance. Methods: In this study, rifampicin-loaded NLC (NLC-RIF) was developed using a hot homogenization with a low energy method and characterized in terms of particle size, polydispersity index, zeta potential, encapsulation efficiency, colloidal stability, and drug loading. Results: In vitro release studies under sink conditions demonstrated a biphasic release pattern, best described by the Korsmeyer–Peppas model, suggesting a combination of diffusion and matrix erosion mechanisms. Antimicrobial activity against S. aureus revealed a substantial increase in potency for NLC-RIF, with an IC50 of 0.46 ng/mL, approximately threefold lower than that of free rifampicin. Cytotoxicity assays in HepG2 cells confirmed over 90% cell viability across all tested concentrations. Conclusions: These findings highlight the potential of NLC-RIF as a biocompatible and effective nanocarrier system for enhancing rifampicin delivery and antibacterial activity.
Source: Pharmaceutics
Authors: Javiera Carrasco-Rojas, Felipe I. Sandoval, Christina M. A. P. Schuh, Carlos F. Lagos, Javier O. Morales, Francisco Arriagada, Andrea C. Ortiz
Language: English
Subfield: Pharmaceutical Science
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,499
Awards: SILK-PEV A NANO-DELIVERY BASED WOUND PATCH TO REDUCE INFLAMMATION AND SCARRING IN SECOND DEGREE BURN WOUNDS, ANTIBIOFILM PEPTIDE-FUNCTIONALIZED MUCOADHESIVE PLATFORM FOR DELIVERY OF A TARGETED NANOSTRUCTURED LIPID CARRIERS A NOVEL VEHICLE INTENDED FOR ANTIBACTERIAL THERAPEUTICS, G3265075560, DESARROLLO DE UN SISTEMA GASTRORETENTIVO NANOESTRUCTURADO PARA EL TRATAMIENTO DE HELICOBACTER PYLORI ENFOQUE IN VITRO E IN VIVO, G6324544734, COMBINING MECHANOBIOLOGY AND NANOMEDICINE TO ELUCIDATE THE ANTI-INFLAMMATORY EFFECT OF APIS MELLIFERA DERIVED ROYAL JELLY EXTRACELLULAR VESICLES IN NEUROINFLAMMATION, G6866384028, G68802833, G7007120338, G7271675693, G7512121943, A RATIONAL STRATEGY TO ENHANCE THE BUCCAL PERMEATION OF STABLE PEPTIDE-LOADED NANOCARRIERS ELUCIDATING KEY PHYSICOCHEMICAL PROPERTIES OF NANOCARRIERS AND THEIR VEHICLE, G7828567163, G8422199472, G8431043412, CENTRO DE ESTUDIOS AVANZADOS DE ENFERMEDADES CRONICAS (ACCDIS), IMPLEMENTACION DE UNA PLATAFORMA PARA CARACTERIZAR NANOESTRUCTURAS (TAMANO POTENCIAL ZETA CONCENTRACION Y FLUORESCENCIA) DE INTERES EN DIVERSAS DISCIPLINAS., CENTRO CIENTIFICO TECNOLOGICO DE EXCELENCIA CIENCIA & VIDA (CIENCIA & VIDA), MULTI-SPECIFIC PEPTIDES FOR HYPERTENSION AND HEART FAILURE POWERED BY TAILORED DRUG DELIVERY SYSTEMS, G95638595, G99091514
OpenAlex ID: W4411452297